Table 1 Demographics, clinical examination at baseline, diagnosis and treatment
ID | Sex | Eye | Age at diagnosis | Associated symptoms | Initial CDVA (LogMAR) | Final CDVA (LogMAR) | Previous known systemic vasculitis | Previous systemic treatment | New diagnosis of systemic vasculitis | Intraveinous corticosteroids pulses (1 g), n | Steroid-sparing first line therapy | Recurrence | Second line therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | OD | 45 | – | 0.7 | 1 | Rheumatoid arthritis | Rituximab | No | 1 | Tapered oral corticosteroids + Rituximab | No | No |
2 | F | OS | 38 | – | 1 | 1 | Relapsing polychondritis | No | No | 3 | Tapered oral corticosteroids + methotrexate | Yes | Cyclophosphamide |
3 | F | OS | 74 | – | 0.4 | 0.4 | No | No | Cryoglobulinemia type 2B | 3 | Tapered oral corticosteroids + Infliximab | No | No |
4 | F | OS | 56 | Scleritis | – | – | Rheumatoid arthritis | Methotrexate, Etanercept | No | 3 | Tapered oral corticosteroids + Rituximab | No | No |
5 | F | OD | 54 | Scleritis, Episcleritis | 1 | 1 | No | No | Granulomatosis with polyangiitis | 5 | Tapered oral corticosteroids | Yes | Cyclophosphamide |
6 | M | OS | 33 | – | 0.4 | 0.9 | No | No | Connective-tissue disease | 4 | Tapered oral corticosteroids + methotrexate | Yes | Cyclophosphamide |
Mean ± SD | 0.7 ± 0.3 | 0.9 ± 0.3 | |||||||||||
P value * | 0.18 | ||||||||||||